Xeris Biopharma Holdings, Inc. $XERS Shares Acquired by Voya Investment Management LLC

Voya Investment Management LLC lifted its holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 866.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 400,079 shares of the company’s stock after buying an additional 358,689 shares during the period. Voya Investment Management LLC owned approximately 0.25% of Xeris Biopharma worth $3,257,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of XERS. Cetera Investment Advisers raised its holdings in Xeris Biopharma by 3.9% in the 2nd quarter. Cetera Investment Advisers now owns 46,332 shares of the company’s stock valued at $216,000 after acquiring an additional 1,735 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of Xeris Biopharma by 7.6% in the second quarter. China Universal Asset Management Co. Ltd. now owns 32,167 shares of the company’s stock valued at $150,000 after purchasing an additional 2,264 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Xeris Biopharma by 7.0% in the second quarter. The Manufacturers Life Insurance Company now owns 54,472 shares of the company’s stock valued at $254,000 after purchasing an additional 3,562 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Xeris Biopharma by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock worth $461,000 after buying an additional 3,594 shares in the last quarter. Finally, Federated Hermes Inc. lifted its position in Xeris Biopharma by 0.5% during the second quarter. Federated Hermes Inc. now owns 691,381 shares of the company’s stock worth $3,229,000 after buying an additional 3,598 shares in the last quarter. 42.75% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

XERS has been the subject of several analyst reports. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Xeris Biopharma in a report on Friday, November 7th. Zacks Research lowered shares of Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Xeris Biopharma in a research report on Wednesday, October 8th. Barclays started coverage on shares of Xeris Biopharma in a report on Monday, December 8th. They issued an “overweight” rating and a $9.00 target price on the stock. Finally, Piper Sandler increased their price target on shares of Xeris Biopharma from $6.00 to $8.00 and gave the company a “neutral” rating in a research note on Friday, November 7th. Six analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Xeris Biopharma has an average rating of “Moderate Buy” and an average price target of $9.50.

Xeris Biopharma Stock Up 2.2%

NASDAQ:XERS opened at $7.37 on Friday. Xeris Biopharma Holdings, Inc. has a 52 week low of $3.14 and a 52 week high of $10.08. The stock’s fifty day moving average is $7.73 and its two-hundred day moving average is $6.96. The stock has a market capitalization of $1.22 billion, a price-to-earnings ratio of -73.69 and a beta of 0.57.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings data on Thursday, November 6th. The company reported $0.00 earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.01). The firm had revenue of $74.38 million during the quarter, compared to analyst estimates of $74.19 million. On average, sell-side analysts expect that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current fiscal year.

Insider Transactions at Xeris Biopharma

In related news, Director Barbara-Jean A. Bormann-Kennedy sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $7.09, for a total transaction of $106,350.00. Following the sale, the director directly owned 142,500 shares of the company’s stock, valued at $1,010,325. This represents a 9.52% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider John Patrick Shannon, Jr. sold 23,242 shares of the stock in a transaction that occurred on Thursday, November 13th. The stock was sold at an average price of $7.46, for a total transaction of $173,385.32. Following the sale, the insider owned 2,643,153 shares in the company, valued at approximately $19,717,921.38. This trade represents a 0.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 206,976 shares of company stock valued at $1,497,495. 6.47% of the stock is owned by insiders.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.